- The key vendor in the Sickle-cell Anemia Therapeutics Market in the US 2015-2019 is Bristol-Myers Squibb Co.
London, 06 January 2015: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Sickle-cell Anemia Therapeutics Market in the US 2015-2019. Increasing focus on adult patients is one key trend in this market, which is anticipated to provide better healthcare services to adult patients and improve their quality of life. The Sickle-cell Anemia Therapeutics market in the US is expected to post a CAGR of 17.10 percent during the period 2014-2019.
People suffering from sickle-cell anemia often undergo blood transfusions to overcome splenic crisis associated with the disease and to treat anemia. At present, there is only one approved drug for the treatment of sickle-cell anemia in the US: Droxia by Bristol-Myers Squibb.
As the Sickle-cell Anemia Therapeutics market in the US is served by only one drug, pipeline drugs for sickle-cell anemia are anticipated to face minimal competition post launch. Also, drugs that are able to demonstrate better efficacy and safety than the currently approved drug are expected to penetrate the market quickly as the market is currently underserved.
“Early-stage diagnosis can also help in avoiding long-term complications that can develop secondary to the disease,” says Faisal Ghaus, Vice President of TechNavio Research.
“Once the initial screening test indicates sickle-cell anemia, diagnostic tests are performed to confirm the presence of the disease and treatment is initiated on confirmation.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
